Revenue
$441.3M
▲ 13.6% YoY
Net Income
$9.8M
▲ 173.1% YoY
EPS
$0.21
▲ 165.6% YoY
Cash
$64.9M
▲ 21.4% YoY
FY 2025 · As of 2025-12-31
Last 90 days
| Insider | Type | Date | Shares | Price | Value | |
|---|---|---|---|---|---|---|
Holloway Jean F SVP, General Counsel | Sell | Mar 4, 2026 | 9.0K | $38.00 | $341K | Form 4 ↗ |
Horton Amy VP, Chief Accounting Officer | Sell | Mar 3, 2026 | 901 | $37.78 | $34K | Form 4 ↗ |
Holloway Jean F SVP, General Counsel | Sell | Mar 3, 2026 | 3.8K | $37.78 | $145K | Form 4 ↗ |
Stanton Marshall S. SVP, Clinical & MD Affair | Sell | Mar 3, 2026 | 2.1K | $37.78 | $81K | Form 4 ↗ |
Davis John E Chief Commercial Officer | Sell | Mar 3, 2026 | 4.6K | $37.78 | $173K | Form 4 ↗ |
Berry Lance A EVP, COO, CFO & Treasurer | Sell | Mar 3, 2026 | 6.3K | $37.78 | $239K | Form 4 ↗ |
Mackin James P President & CEO | Sell | Mar 3, 2026 | 17.9K | $37.78 | $676K | Form 4 ↗ |
Horton Amy VP, Chief Accounting Officer | Grant | Mar 2, 2026 | 7.5K | $0.00 | $0 | Form 4 ↗ |
Holloway Jean F SVP, General Counsel | Grant | Mar 2, 2026 | 27.8K | $0.00 | $0 | Form 4 ↗ |
Stanton Marshall S. SVP, Clinical & MD Affair | Grant | Mar 2, 2026 | 21.8K | $0.00 | $0 | Form 4 ↗ |
Davis John E Chief Commercial Officer | Grant | Mar 2, 2026 | 28.8K | $0.00 | $0 | Form 4 ↗ |
Berry Lance A EVP, COO, CFO & Treasurer | Grant | Mar 2, 2026 | 40.9K | $0.00 | $0 | Form 4 ↗ |
Mackin James P President & CEO | Grant | Mar 2, 2026 | 116.9K | $0.00 | $0 | Form 4 ↗ |
Horton Amy VP, Chief Accounting Officer | Sell | Mar 2, 2026 | 641 | $38.02 | $24K | Form 4 ↗ |
Stanton Marshall S. SVP, Clinical & MD Affair | Sell | Mar 2, 2026 | 1.5K | $38.02 | $58K | Form 4 ↗ |
Mackin James P President & CEO | Sell | Mar 2, 2026 | 14.9K | $38.02 | $567K | Form 4 ↗ |
Holloway Jean F SVP, General Counsel | Sell | Mar 2, 2026 | 2.2K | $38.02 | $83K | Form 4 ↗ |
Berry Lance A EVP, COO, CFO & Treasurer | Sell | Mar 2, 2026 | 5.2K | $38.02 | $197K | Form 4 ↗ |
Davis John E Chief Commercial Officer | Sell | Mar 2, 2026 | 2.8K | $38.02 | $106K | Form 4 ↗ |